

## Bleselumab

Cat. No.:	HY-P99257
CAS No.:	1453067-91-8
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity ( $K_d$ : 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	CD40 <sup>[1]</sup>									
<b>In Vitro</b>	<p>Bleselumab (0-1 µg/mL, 48 h) dose-dependently inhibits PBMCs proliferation induced by soluble CD154<sup>[2]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.            Cell Viability Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>PBMCs</td> </tr> <tr> <td>Concentration:</td> <td>0-1 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited PBMC proliferation induced by shCD154 in human, cynomolgus monkey and rabbit blood samples.</td> </tr> </table>		Cell Line:	PBMCs	Concentration:	0-1 µg/mL	Incubation Time:	48 h	Result:	Inhibited PBMC proliferation induced by shCD154 in human, cynomolgus monkey and rabbit blood samples.
Cell Line:	PBMCs									
Concentration:	0-1 µg/mL									
Incubation Time:	48 h									
Result:	Inhibited PBMC proliferation induced by shCD154 in human, cynomolgus monkey and rabbit blood samples.									
<b>In Vivo</b>	<p>Bleselumab (0.1-10 mg/kg, i.v.) inhibits Delayed-type hypersensitivity (DTH) reaction in cynomolgus monkeys<sup>[2]</sup>.            Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys<sup>[3]</sup>.            Bleselumab (2 or 5 mg/kg, i.v.) together with <a href="#">Tacrolimus</a> (HY-13756) shows a longer median survival time (MST) than monotherapy<sup>[3]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus monkeys<sup>[2]</sup>.</td> </tr> <tr> <td>Dosage:</td> <td>0.1, 1 and 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection (i.v.)</td> </tr> <tr> <td>Result:</td> <td>Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner.</td> </tr> </table>		Animal Model:	Cynomolgus monkeys <sup>[2]</sup> .	Dosage:	0.1, 1 and 10 mg/kg	Administration:	Intravenous injection (i.v.)	Result:	Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner.
Animal Model:	Cynomolgus monkeys <sup>[2]</sup> .									
Dosage:	0.1, 1 and 10 mg/kg									
Administration:	Intravenous injection (i.v.)									
Result:	Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner.									

---

## REFERENCES

- [1]. Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171.
- [2]. Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9.
- [3]. Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA